DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* ADOCIA *


 

2005 - Rhône-Alpes
Lyon
www.no-website.net

 

Discovery, Drugs
Key words: Growth factors, Natural proteins, Regenerating organs, Osteoporosis, Diabetes, Aging population, BioChaperone
Mission: to develop innovative drugs for regenerating organs affected by diseases related to the aging of the population, such as osteoporosis and diabetes
Clients: Pharmaceutical industry
g.soula@adocia.com

Age: 11 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Soula (Gérard) [born 1945, ex-Rhône Poulenc, Flamel Technologies (founder)]
Sc.Dir.-CSO: Soula (Olivier) [born 1970, PhD polymer science, MBA-IAE (Lyon), ex-Flamel Technologies]
Fin.Dir.-CFO: Danaguezian (Valérie)
BusDev: Soula (Rémi)
Financers (Hist.): AGF P.E., Bioam Gestion, Société Générale A.M., Viveris Management, Business angels (Alain Tornier and Jean Deléage [died in 2011]), InnoBio, SHAM (Société Hospitalière d'Assurances Mutuelles)

Turnover (M€) : n.a.
Total funding (M€) : 55.0
Last funding (M€) : 27.4
Focus : Multiple
Position : Clinical
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2012 .06 Patent : granted on BioChaperone PDGF (Platelet Derived Growth Factor) formulations for chronic wound treatment, including Diabetic Foot Ulcer, in USA (USPTO) and Europe (EPO) LEGAL [6 years]
2012 .04 Clinical trials (phase II) with PDGF-BB for the treatment of diabetic foot ulcer, compared with current standard Regranex (results, phase III planned to start end of 2012) CLIN [6 years]
2012 .02 Listing on Euronext : 25.3 M€ (IPO), extended to 27.4 M€ in April PBO [6 years]
2011 .06 Clinical trials (phase II) with BioChaperone technology combined with 2 therapeutic proteins, Platelet Derived Growth Factor, fast-acting human insulin (completed) CLIN [5 years]
2011 .03 Clinical trial (phase I) for HinsBet, a fast-acting human insulin (completed, positive, with phase IIa, started in May) CLIN [5 years]
2010 .01 2nd round-financing : 14.0 M€, by InnoBio (for 6 M€), SHAM (for 2 M€), and previous shareholders, including the founders RFINB [4 years]
2008 .04 1st round-financing : 12.0 M€, by AGF P.E., Société Générale A.M., Bioam Gestion, Vivéris Management RFINA [2 years]
2007 .00 Financing (no interest loan) : 2.25 M€, by Oseo, for its osteoporosis project DEBT [1 year]
2005 .12 Company founded by Gérard Soula (ex-Flamel Technologies, CEO, during 15 years), and his 2 sons, Olivier (born 1970) and Rémy, initially named PPM (Proteins & Peptides Management), investing 1.6 M€ ORGF [0 year]

Actualisation / Updating: 26-Oct-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende